Dr. Reddy's Laboratories Limited (RDY:NYSE) closed at $13.07 on October 19, 2026, down 0.04% on the day. The stock trades 16.6% below its 52-week high of $15.67 and 15.0% above its 52-week low of $11.36. Over the past year, it lost 9.6%. Dr. Reddy's Laboratories Limited is part of the Health Care sector (Major Pharmaceuticals).
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| +1.95% | +7.22% | +4.31% | -0.15% | -9.55% |
In 252 trading sessions since October 16, 2025, RDY closed higher on 124 days (49%). Its best day was April 23, 2026 (+5.76%) and its worst was July 22, 2026 (-9.39%). It never moved 10% or more in a single session.
Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets finished pharmaceutical products as branded formulations or generic finished dosages. This segment also engages in biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients (APIs) and intermediates, which are used as principal ingredients for finished pharmaceutical products. This segment also offers contract research services; and manufactures and sells APIs and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and manufacture of differentiated formulations and new chemical entities (NCEs) for dermatology and neurology therapeutic areas. It also engages in the discovery, development, and commercialization of novel small molecule agents in therapeutic areas, such as metabolic disorders, and pain and inflammation; and has a portfolio of in-licensed patented dermatology products. As of Ma...
Find more stocks like RDY with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.